| Increased survival with enzalutamide in prostate cancer after chemotherapy HI Scher, K Fizazi, F Saad, ME Taplin, CN Sternberg, K Miller, R De Wit, ... New England Journal of Medicine 367 (13), 1187-1197, 2012 | 4779 | 2012 |
| Abiraterone and increased survival in metastatic prostate cancer JS De Bono, CJ Logothetis, A Molina, K Fizazi, S North, L Chu, KN Chi, ... New England Journal of Medicine 364 (21), 1995-2005, 2011 | 4763 | 2011 |
| Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers PC Fong, DS Boss, TA Yap, A Tutt, P Wu, M Mergui-Roelvink, P Mortimer, ... New England Journal of Medicine 361 (2), 123-134, 2009 | 4088 | 2009 |
| Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial JS De Bono, S Oudard, M Ozguroglu, S Hansen, JP Machiels, I Kocak, ... The Lancet 376 (9747), 1147-1154, 2010 | 3747 | 2010 |
| Integrative clinical genomics of advanced prostate cancer D Robinson, EM Van Allen, YM Wu, N Schultz, RJ Lonigro, JM Mosquera, ... Cell 161 (5), 1215-1228, 2015 | 3204 | 2015 |
| Enzalutamide in metastatic prostate cancer before chemotherapy TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... New England Journal of Medicine 371 (5), 424-433, 2014 | 3073 | 2014 |
| Abiraterone in metastatic prostate cancer without previous chemotherapy CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ... New England Journal of Medicine 368 (2), 138-148, 2013 | 2996 | 2013 |
| Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer JS De Bono, HI Scher, RB Montgomery, C Parker, MC Miller, H Tissing, ... Clinical cancer research 14 (19), 6302-6309, 2008 | 2358 | 2008 |
| DNA-repair defects and olaparib in metastatic prostate cancer J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ... New England Journal of Medicine 373 (18), 1697-1708, 2015 | 2084 | 2015 |
| Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage … ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ... The Lancet 387 (10024), 1163-1177, 2016 | 1904 | 2016 |
| Abiraterone for prostate cancer not previously treated with hormone therapy ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ... New England Journal of Medicine 377 (4), 338-351, 2017 | 1549 | 2017 |
| Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo … K Fizazi, HI Scher, A Molina, CJ Logothetis, KN Chi, RJ Jones, ... The lancet oncology 13 (10), 983-992, 2012 | 1548 | 2012 |
| Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall … CJ Ryan, MR Smith, K Fizazi, F Saad, PFA Mulders, CN Sternberg, ... The Lancet Oncology 16 (2), 152-160, 2015 | 1395 | 2015 |
| Inherited DNA-repair gene mutations in men with metastatic prostate cancer CC Pritchard, J Mateo, MF Walsh, N De Sarkar, W Abida, H Beltran, ... N Engl J Med 375, 443-453, 2016 | 1389 | 2016 |
| Patient-derived organoids model treatment response of metastatic gastrointestinal cancers G Vlachogiannis, S Hedayat, A Vatsiou, Y Jamin, J Fernández-Mateos, ... Science 359 (6378), 920-926, 2018 | 1217 | 2018 |
| Olaparib for metastatic castration-resistant prostate cancer J de Bono, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ... New England Journal of Medicine 382 (22), 2091-2102, 2020 | 1209 | 2020 |
| Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval PC Fong, TA Yap, DS Boss, CP Carden, M Mergui-Roelvink, C Gourley, ... Journal of clinical oncology 28 (15), 2512-2519, 2010 | 1077 | 2010 |
| Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3 HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ... Journal of Clinical Oncology 34 (12), 1402, 2016 | 1068 | 2016 |
| Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostrate cancer commonly remains hormone driven G Attard, AH Reid, TA Yap, F Raynaud, M Dowsett Journal of clinical oncology 26 (28), 4563-4571, 2008 | 1034 | 2008 |
| Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ... European urology 73 (2), 178-211, 2018 | 766* | 2018 |
